Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer

Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer

US Patent 12472272 · Granted Nov 18, 2025

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Dual mode 18F-labelled theranostic compounds and uses thereof2025
Dual mode 18F-labelled theranostic compounds and uses thereof2025
Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor2025
Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormo2024
Cyclic peptide analogs of melanocortin and amanitin and methods of making such2024
Radiolabeled compounds targeting the prostate-specific membrane antigen2022
Radiolabeled compounds targeting the prostate-specific membrane antigen2022
Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormo2022
Cyclic peptide analogs of melanocortin and amanitin and methods of making such2022
18/19F-labelled compounds which target the prostate specific membrane antigen2021
18/19F-labelled compounds which target the prostate specific membrane antigen2021
Image sensor packages2019